Robert Nelsen Denali Therapeutics Inc. (DNLI) insider trading activity

DNLI Quotes by TradingView

Robert Nelsen is Director of Denali Therapeutics Inc.. Currently has a direct ownership of 12,432 shares of DNLI, which is worth approximately $301,103. The most recent transaction as insider was on Jun 02, 2021, when has been sold 2,074 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 12.4K
0% 3M change
0% 12M change
Total Value Held $301,103

ROBERT NELSEN Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 02 2021
BUY
Grant, award, or other acquisition
-
2,074 Added 14.3%
12,432 Common Stock
Jun 01 2021
BUY
Exercise of conversion of derivative security
-
3,253 Added 23.9%
10,358 Common Stock
May 12 2021
BUY
Other acquisition or disposition
-
2,537 Added 26.31%
7,105 Common Stock
Mar 22 2021
BUY
Other acquisition or disposition
-
2,538 Added 35.72%
4,568 Common Stock

Also insider at

BEAM
Beam Therapeutics Inc. Healthcare
Director
KRTX
Karuna Therapeutics, Inc. Healthcare
Director
SANA
Sana Biotechnology, Inc. Healthcare
VIR
Vir Biotechnology, Inc. Healthcare
Director
LYEL
Lyell Immunopharma, Inc. Healthcare
PRME
Prime Medicine, Inc.
Director
RN

Robert Nelsen

Director
Chicago, IL

Track Institutional and Insider Activities on DNLI

Follow Denali Therapeutics Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells DNLI shares.

Notify only if

Insider Trading

Get notified when an Denali Therapeutics Inc. insider buys or sells DNLI shares.

Notify only if

News

Receive news related to Denali Therapeutics Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on DNLI